AXM Pharma Receives $700,000 Purchase Order on First Sunkist Sales

Market Wire, March, 2005

AXM Pharma, Inc. (AMEX: AXJ) announced today that it received a $700,000 purchase order for immediate delivery from the launch of the Sunkist brand of nutritional supplements. The purchase order came from Zeullig Hong Kong. Hong Kong is the smallest territory in which AXM operates. With the first purchase order in Hong Kong, the combined resources of AXM and Zuellig in Hong Kong will total 12 people on the ground and 3 managers. Zuellig (http://www.zuelligpharma.com) is a subsidiary of the Interpharma Group, which is the largest pharmaceutical distributor in Asia, with annual revenues exceeding US$ 3.0 billion, 125 multinational clients, more than 100,000 direct accounts and 4,000 employees.

"Today marks the beginning of AXM Pharma's transition to a significant pharmaceutical manufacturing and marketing force in the Asian markets," said Doug MacLellan, Vice Chairman of AXM Pharma. "This $700,000 purchase order is the first in a series of orders that are expected to come month after month as AXM Pharma ramps up sales and rolls out a full-fledged sales & marketing organization," he added.

AXM Pharma's full product line includes Elegance, LiveComf, Bodyward, Reheal and LifeGate, Sunkist dissolve-in-the-mouth films and Chew Chew Gummy vitamin products including Vitamin C, zinc lozenge, Echinacea, and other nutraceutical products. AXM Pharma has 42 licenses, which include but are not limited to: Asarone, which is manufactured in tablet form, is indicated for bronchial infection and bronchial constriction (symptoms of upper respiratory infection); Weifukang, an antiseptic cream for cleansing acne and for relieving the symptoms of eczema, psoriasis and other skin irritations, such as contact dermatitis; and Qiyao, an adjunctive therapy for Type II diabetes.

AXM Pharma Inc., http://www.axmpharma.com, through its wholly owned subsidiary, Werke Pharmaceuticals, Inc., is the 100% owner of AXM Pharma Shenyang, Inc. ("AXM Shenyang"), a Wholly Foreign Owned Enterprise ("WFOE") under the laws of the People's Republic of China. AXM Shenyang is located in the City of Shenyang, in the Province of Liaoning, China. AXM Shenyang and its predecessor company Shenyang Tianwei Pharmaceutical Factory, Ltd. ("STPF"), has an operating history of approximately 10 years. AXM Shenyang historically has been a manufacturer and distributor of proprietary and generic pharmaceutical products, which include injectables, capsules, tablets, liquids and medicated skin products for export and domestic Chinese sales. For additional information on AXM Pharma Inc, please visit http://www.iccinfo.com or call Investor Communications Company, LLC at 866 562 0134.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this news release include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products and prices. With respect to AXM, except for the historical information contained herein, the matters discussed in this news release are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, AXM's extremely limited operating history, uncertainties related to the Company's access to additional capital, competition and dependence on key management.

Contact: Contact Information: Tom Bostic Investor Communications Company, LLC (866) 562-0134